Bo‐Eric Persson

2.3k total citations · 1 hit paper
47 papers, 1.8k citations indexed

About

Bo‐Eric Persson is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Bo‐Eric Persson has authored 47 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 16 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Molecular Biology. Recurrent topics in Bo‐Eric Persson's work include Prostate Cancer Treatment and Research (32 papers), Hormonal and reproductive studies (16 papers) and Prostate Cancer Diagnosis and Treatment (14 papers). Bo‐Eric Persson is often cited by papers focused on Prostate Cancer Treatment and Research (32 papers), Hormonal and reproductive studies (16 papers) and Prostate Cancer Diagnosis and Treatment (14 papers). Bo‐Eric Persson collaborates with scholars based in Denmark, United States and Sweden. Bo‐Eric Persson's co-authors include Tine Kold Olesen, L Boccon-Gibod, Neal D. Shore, Fritz H. Schröder, Laurence Klotz, Gunnar Ronquist, Bertrand Tombal, Jens-Kristian Jensen, P. Cantor and Kurt Miller and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Urology.

In The Last Decade

Bo‐Eric Persson

47 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

2008 447 citations Laurence Klotz, L Boccon-Gibod et al. British Journal of Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bo‐Eric Persson Denmark	18	1.4k	856	271	262	219	47	1.8k
Tine Kold Olesen Denmark	15	1.3k 0.9×	854 1.0×	275 1.0×	268 1.0×	155 0.7×	45	1.5k
Jean Emond Canada	14	1.0k 0.7×	516 0.6×	168 0.6×	140 0.5×	196 0.9×	27	1.3k
W.B. Peeling United Kingdom	24	1.2k 0.9×	480 0.6×	131 0.5×	141 0.5×	239 1.1×	64	1.8k
S.-O. Andersson Sweden	10	794 0.6×	463 0.5×	125 0.5×	414 1.6×	578 2.6×	12	1.5k
Sumit Isharwal United States	14	1.0k 0.8×	231 0.3×	191 0.7×	339 1.3×	549 2.5×	33	1.4k
Göran Ahlgren Sweden	18	943 0.7×	158 0.2×	49 0.2×	135 0.5×	174 0.8×	45	1.2k
Tony T. Wu Taiwan	15	542 0.4×	135 0.2×	91 0.3×	187 0.7×	382 1.7×	32	1.1k
M K Brawer United States	21	811 0.6×	92 0.1×	44 0.2×	135 0.5×	226 1.0×	36	1.1k
Arne Strauß Germany	17	569 0.4×	91 0.1×	120 0.4×	127 0.5×	453 2.1×	61	1.1k
Christian Wülfing Germany	22	786 0.6×	66 0.1×	98 0.4×	356 1.4×	629 2.9×	113	1.9k

Countries citing papers authored by Bo‐Eric Persson

Since Specialization

Citations

This map shows the geographic impact of Bo‐Eric Persson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo‐Eric Persson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo‐Eric Persson more than expected).

Fields of papers citing papers by Bo‐Eric Persson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo‐Eric Persson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo‐Eric Persson. The network helps show where Bo‐Eric Persson may publish in the future.

Co-authorship network of co-authors of Bo‐Eric Persson

This figure shows the co-authorship network connecting the top 25 collaborators of Bo‐Eric Persson. A scholar is included among the top collaborators of Bo‐Eric Persson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bo‐Eric Persson. Bo‐Eric Persson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iversen, Peter, Jan‐Erik Damber, Anders Malmberg, Bo‐Eric Persson, & Laurence Klotz. (2015). Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials. Therapeutic Advances in Urology. 8(2). 75–82. 13 indexed citations

Klotz, Laurence, Kurt Miller, E. David Crawford, et al.. (2014). Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists. European Urology. 66(6). 1101–1108. 85 indexed citations

Crawford, E. David, Neal D. Shore, Judd W. Moul, et al.. (2014). Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix. Urology. 83(5). 1122–1128. 43 indexed citations

Anderson, John, Manfred Wirth, Francisco Gómez Veiga, et al.. (2012). Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233). Urologia Internationalis. 90(3). 321–328. 46 indexed citations

Crawford, E. David, Bertrand Tombal, Kurt Miller, et al.. (2011). A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer. The Journal of Urology. 186(3). 889–897. 118 indexed citations

Tombal, Bertrand, Kurt Miller, L Boccon-Gibod, et al.. (2009). Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics. European Urology. 57(5). 836–842. 116 indexed citations

Schröder, Fritz H., Bertrand Tombal, Kurt Miller, et al.. (2009). Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12‐month, comparative, phase III study. British Journal of Urology. 106(2). 182–187. 58 indexed citations

Persson, Bo‐Eric, Tine Kold Olesen, & Jens-Kristian Jensen. (2009). Degarelix: A New Approach for the Treatment of Prostate Cancer. Neuroendocrinology. 90(3). 235–244. 20 indexed citations

Klotz, Laurence, L Boccon-Gibod, Neal D. Shore, et al.. (2008). The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer. British Journal of Urology. 102(11). 1531–1538. 447 indexed citations breakdown →

10.

Huhtaniemi, Ilpo, et al.. (2008). Will GnRH antagonists improve prostate cancer treatment?. Trends in Endocrinology and Metabolism. 20(1). 43–50. 48 indexed citations

11.

Tombal, Bertrand, Peter Iversen, Hendrik Van Poppel, et al.. (2006). Determining the dose of degarelix for effective therapy of prostate cancer patients as investigated by the degarelix study groups. Annals of Oncology. 17. 150–150. 2 indexed citations

12.

See, William A., Manfred Wirth, David G. McLeod, et al.. (2002). Immediate treatment with bicalutamide reduces the risk of disease progression in early non-metastatic prostate cancer irrespective of primary therapy. European Urology Supplements. 1(1). 136–136. 3 indexed citations

13.

Nilsson, B. Ove, et al.. (1998). Monoclonal antibodies against human prostasomes. The Prostate. 35(3). 178–184. 34 indexed citations

14.

Persson, Bo‐Eric & Gunnar Ronquist. (1996). Allopurinol Treatment Results inElevated Prostate-Specific AntigenLevels in Prostatic Fluid and Serumof Patients with Non-BacterialProstatitis. European Urology. 29(1). 111–114. 7 indexed citations

15.

Çıray, H. Nadir, Bo‐Eric Persson, Godfried M. Roomans, & U. Ulmsten. (1995). Dye‐coupling between term pregnant human myometrial cells before labor: Carboxyfluorescein versus lucifer yellow. Cell Biology International. 19(7). 609–618. 6 indexed citations

16.

Çıray, H. Nadir, Bo‐Eric Persson, Torbjörn Bäckström, Godfried M. Roomans, & U. Ulmsten. (1994). Direct intracellular injections for studying human myometrial gap junctions prior to labor. Acta Obstetricia Et Gynecologica Scandinavica. 73(2). 97–102. 1 indexed citations

17.

Persson, Bo‐Eric, et al.. (1989). Effect of bumetanide on tubuloglomerular feedback in Necturus maculosus. Acta Physiologica Scandinavica. 137(1). 93–99. 1 indexed citations

18.

Persson, Bo‐Eric & A. Erik G. Persson. (1983). Acidification in the distal tubule of the Amphiuma kidney. Acta Physiologica Scandinavica. 117(3). 343–349. 5 indexed citations

19.

Persson, Bo‐Eric & A. Erik G. Persson. (1981). The existence of a tubulo-glomerular feedback mechanism in the Amphiuma nephron. Pflügers Archiv - European Journal of Physiology. 391(2). 129–134. 10 indexed citations

20.

Persson, Bo‐Eric. (1978). Dynamics and regulation of glomerular ultrafiltration in the Amphiuma kidney. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact